跳至主要内容
临床试验/NCT04554797
NCT04554797Unknown不适用

Regional Hypothermia in Combination With Endovascular Thrombectomy in Acute Ischemic Stroke

Capital Medical University2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2020年10月16日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
60
试验地点
2
主要终点
Rate of any major adverse events

研究概览

简要总结

The investigators have previous shown that regional hypothermia by the intra-arterial infusion of cold saline combined with mechanical thrombectomy in acute ischemic stroke is feasible and safe. The safety of selective brain cooling in patients undergoing mechanical thrombectomy, however, is not established in a randomized trial. The investigators therefore conducted this RCT study to further explore the safety of regional hypothermia in patients with acute ischemic stroke who underwent mechanical thrombectomy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥18 and ≤80
  • Clinical signs consistent with the diagnosis of an acute ischemic stroke
  • Baseline NIHSS score obtained prior to randomization ≥8
  • Intracranial arterial occlusion of the distal intracranial carotid artery or
  • Middle (M1/M2), demonstrated with CTA, MRA, DSA
  • The possibility to start treatment (artery puncture) within 6 hours from onset
  • Regional hypothermia is expected to start within 15 minutes after recanalization
  • Informed consent given

排除标准

  • mTICI<2b after endovascular treatment
  • No significant pre-stroke disability (mRS ≤1)
  • Previous NYHA grade > 1
  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with INR > 3.0
  • Baseline platelet count < 50000/µL
  • Baseline blood glucose of < 50mg/dL or >400mg/dl
  • Severe, sustained hypertension (SBP > 220 mm Hg or DBP > 110 mm Hg). NOTE: If the blood pressure can be successfully reduced and maintained at the acceptable level using local treatment guidelines recommended medication (including iv antihypertensive drips), the patient can be enrolled.
  • Seizures at stroke onset which would preclude obtaining a baseline NIHSS
  • Subjects who have received iv t-PA treatment beyond 4,5 hours from the beginning of the symptoms
  • Renal insufficiency with creatinine ≥ 3 mg/dl
  • Woman of childbearing potential who is known to be pregnant or lactating
  • Subject participating in a study involving an investigational drug or device that would impact this study
  • Cerebral vasculitis
  • Patients with a pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations
  • Unlikely to be available for 3 months follow-up (e.g. no fixed home address, visitor from overseas).
  • CT or MR evidence of hemorrhage (the presence of microbleeds on MRI is allowed)
  • ASPECT<6
  • Subjects with occlusions in multiple vascular territories (anterior circulation and posterior circulation)
  • Evidence of intracranial tumor (except small meningioma)

结局指标

主要结局

Rate of any major adverse events

时间窗: 7 days

次要结局

  • Rate of symptomatic intracerebral hemorrhage(24 hours)
  • NIHSS(7 days or discharge)
  • Final infarct volume(5-7 days)
  • Modified Rankin scale(90 days)
  • Rate of intracerebral hemorrhage(24 hours)
  • Rate of death(90 days)

研究者

发起方
Capital Medical University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ji Xunming,MD,PhD

Professor

Capital Medical University

研究点 (2)

Loading locations...

相似试验